Search results for "copeptin"

showing 6 items of 16 documents

Multiple marker approach to risk stratification in patients with stable coronary artery disease

2010

Aims Multimarker approaches for risk prediction in coronary artery disease have remained inconsistent. We assessed multiple biomarkers representing distinct pathophysiological pathways in relation to cardiovascular events in stable angina. Methods and results We investigated 12 biomarkers reflecting inflammation [C-reactive protein, growth-differentiation factor (GDF)-15, neopterin], lipid metabolism (apolipoproteins AI, B100), renal function (cystatin C, serum creatinine), and cardiovascular function and remodelling [copeptin, C-terminal-pro-endothelin-1, mid-regional-pro-adrenomedullin (MR-proADM), mid-regional-pro-atrial natriuretic peptide (MR-proANP), N-terminal-pro-B-type natriuretic …

Malemedicine.hormonemedicine.medical_specialtymedicine.drug_classMyocardial InfarctionCoronary Artery DiseaseKaplan-Meier EstimateRisk AssessmentAnginaCoronary artery diseaseEndothelinsCopeptinInternal medicinemedicineNatriuretic peptideHumansAngina StableProspective StudiesRisk factorAgedbiologybusiness.industryHazard ratioMiddle AgedPrognosismedicine.diseaseEndocrinologyCystatin Cbiology.proteinCardiologyFemaleCardiology and Cardiovascular MedicinebusinessBiomarkersEuropean Heart Journal
researchProduct

High-sensitivity troponin and novel biomarkers for the early diagnosis of non-ST-segment elevation myocardial infarction in patients with atrial fibr…

2015

To evaluate the diagnostic performance of high-sensitivity troponin I (hsTnI) and other novel biomarkers for diagnosing non-ST-segment elevation myocardial infarction (NSTEMI) in patients with atrial fibrillation.In an acute chest pain cohort (N=1673), mean age 61.4±13.6 (34% female), we measured hsTnI and 13 established and novel biomarkers reflecting ischaemia, necrosis, inflammation, myocardial stress, angiogenesis on admission and after three hours in order to investigate their diagnostic accuracy for NSTEMI.In atrial fibrillation patients (N=299) hsTnI on admission had the best discriminatory ability for NSTEMI (area under the curve 0.97) with only two novel biomarkers, copeptin and he…

Malemedicine.medical_specialty030204 cardiovascular system & hematologyCritical Care and Intensive Care MedicineFatty Acid-Binding ProteinsSensitivity and SpecificityBiomarkers PharmacologicalAngina Pectoris03 medical and health sciences0302 clinical medicineCopeptinTroponin TInternal medicineTroponin IAtrial FibrillationmedicineST segmentHumans030212 general & internal medicineMyocardial infarctionProspective StudiesNon-ST Elevated Myocardial InfarctionAgedFibrillationbiologyTroponin Tbusiness.industryGlycopeptidesAtrial fibrillationGeneral Medicinemedicine.diseaseTroponinEarly DiagnosisArea Under Curvebiology.proteinCardiologyFemalemedicine.symptomCardiology and Cardiovascular MedicinebusinessFatty Acid Binding Protein 3European heart journal. Acute cardiovascular care
researchProduct

Multiple biomarkers and atrial fibrillation in the general population.

2014

BACKGROUND: Different biological pathways have been related to atrial fibrillation (AF). Novel biomarkers capturing inflammation, oxidative stress, and neurohumoral activation have not been investigated comprehensively in AF. METHODS AND RESULTS: In the population-based Gutenberg Health Study (n = 5000), mean age 56 ± 11 years, 51% males, we measured ten biomarkers representing inflammation (C-reactive protein, fibrinogen), cardiac and vascular function (midregional pro adrenomedullin [MR-proADM], midregional pro atrial natriuretic peptide [MR-proANP], N-terminal pro-B-type natriuretic peptide [Nt-proBNP], sensitive troponin I ultra [TnI ultra], copeptin, and C-terminal pro endothelin-1), a…

Malemedicine.medical_specialtymedicine.drug_classEpidemiologyPopulationCardiologylcsh:MedicineCopeptinRisk FactorsInternal medicineTroponin IAtrial FibrillationmedicineNatriuretic peptideMedicine and Health SciencesHumansPublic and Occupational Healtheducationlcsh:ScienceAgededucation.field_of_studyMultidisciplinaryModels Statisticalbiologybusiness.industrylcsh:RAtrial fibrillationOdds ratioMiddle Agedmedicine.diseaseTroponinCardiovascular DiseasesPopulation SurveillanceCardiologybiology.proteinBiomarker (medicine)Femalelcsh:QbusinessArrhythmiaBiomarkersResearch ArticlePLoS ONE
researchProduct

Serum Copeptin and Midregion Proadrenomedullin (MR-proADM) After an Ultramarathon

2014

Background Although it is widely acknowledged that physical activity confers several health benefits, it remains uncertain whether strenuous and physically demanding exercise might determine biological effects that might turn to be ultimately unfavorable for health. Copeptin and midregion proadrenomedullin (MR-proADM) are emerging cardiovascular and stress biomarkers, but little is known about the influence of strenuous physical exercise on their concentrations. Methods The present study was performed to investigate the variation of copeptin and MRproADM, along with that of serum creatinine and estimated glomerular filtration rate before and after a 60 km ultramarathon in 16 healthy Caucasi…

Microbiology (medical)medicine.medical_specialtyClinical BiochemistryPopulationRenal functionPhysical exerciseReference rangeHealth benefitschemistry.chemical_compoundCopeptinInterquartile rangeInternal medicineImmunology and AllergyMedicineeducationeducation.field_of_studyCreatininebusiness.industryBiochemistry (medical)Public Health Environmental and Occupational HealthHematologyMedical Laboratory TechnologyEndocrinologychemistryCardiologybusinessJournal of Clinical Laboratory Analysis
researchProduct

Prognostic impact of copeptin in pulmonary embolism: a multicentre validation study.

2018

To externally validate the prognostic impact of copeptin, either alone or integrated in risk stratification models, in pulmonary embolism (PE), we performed a post hoc analysis of 843 normotensive PE patients prospectively included in three European cohorts.Within the first 30 days, 21 patients (2.5%, 95% CI 1.5–3.8) had an adverse outcome and 12 (1.4%, 95% CI 0.7–2.5) died due to PE. Patients with copeptin ≥24 pmol·L−1 had a 6.3-fold increased risk for an adverse outcome (95% CI 2.6–15.5, p<0.001) and a 7.6-fold increased risk for PE-related death (95% CI 2.3–25.6, p=0.001). Risk classification according to the 2014 European Society of Cardiology (ESC) guideline algorithm identified 248…

Pulmonary and Respiratory MedicineMalemedicine.medical_specialtyValidation studyAdverse outcomes030204 cardiovascular system & hematologyRisk Assessment03 medical and health sciences0302 clinical medicineCopeptinRisk groupsRisk FactorsInternal medicinePost-hoc analysismedicineHumansProspective StudiesAgedAged 80 and overbusiness.industryGlycopeptidesMiddle Agedmedicine.diseasePrognosisPulmonary embolismIncreased riskLogistic Models030228 respiratory systemROC CurveRisk stratificationFemalebusinessPulmonary EmbolismAlgorithmsBiomarkersThe European respiratory journal
researchProduct

Mid-regional pro-atrial natriuretic peptide and copeptin as indicators of disease severity and therapy response in CTEPH

2020

Background Chronic thromboembolic pulmonary hypertension (CTEPH) leads to right heart failure. Pulmonary endarterectomy (PEA) or balloon pulmonary angioplasty (BPA) restore pulmonary haemodynamics and allow cardiac recovery. This study examined the relationship of copeptin and mid-regional pro-atrial natriuretic peptide (MR-proANP) levels to disease severity and therapy response. Methods This observational cohort study included 125 patients (55 PEA/70 BPA) who underwent treatment and completed a 6-/12-month follow-up. Biomarkers, measured at baseline, prior to every BPA and at follow-up, were compared to 1) severe disease at baseline (right atrial pressure (RAP) ≥8 mmHg and cardiac index ≤2…

Pulmonary and Respiratory MedicinePulmonary Vascular Disease7medicine.medical_specialtybusiness.industrymedicine.drug_classmedicine.medical_treatmentlcsh:RArea under the curveCentral venous pressureCardiac indexlcsh:MedicineOriginal Articlesmedicine.anatomical_structureCopeptinInternal medicineAngioplastyVascular resistancemedicineCardiologyNatriuretic peptidebusinessCohort studyERJ Open Research
researchProduct